Research Article

Fluorescence Spectrometric Determination of Drugs Containing α-Methylene Sulfone/Sulfonamide Functional Groups Using N\textsuperscript{1}-Methylnicotinamide Chloride as a Fluorogenic Agent

Khaled M. Elokely, Mohamed A. Eldawy, Mohamed A. Elkersh, and Tarek F. El-Moselhy

Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Tanta University, Tanta 31527, Egypt

Correspondence should be addressed to Tarek F. El-Moselhy, telmoselhy@yahoo.com

Received 19 January 2011; Accepted 14 March 2011

Academic Editor: Alejandro Cifuentes

Copyright © 2011 Khaled M. Elokely et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

A simple spectrofluorometric method has been developed, adapted, and validated for the quantitative estimation of drugs containing α-methylene sulfone/sulfonamide functional groups using N\textsuperscript{1}-methylnicotinamide chloride (NMNCl) as fluorogenic agent. The proposed method has been applied successfully to the determination of methyl sulfonyl methane (MSM) (1), tinidazole (2), rofecoxib (3), and nimesulide (4) in pure forms, laboratory-prepared mixtures, pharmaceutical dosage forms, spiked human plasma samples, and in volunteer’s blood. The method showed linearity over concentration ranging from 1 to 150 μg/mL, 10 to 1000 ng/mL, 1 to 1800 ng/mL, and 30 to 2100 ng/mL for standard solutions of 1, 2, 3, and 4, respectively, and over concentration ranging from 5 to 150 μg/mL, 10 to 1000 ng/mL, 10 to 1700 ng/mL, and 30 to 2350 ng/mL in spiked human plasma samples of 1, 2, 3, and 4, respectively. The method showed good accuracy, specificity, and precision in both laboratory-prepared mixtures and in spiked human plasma samples. The proposed method is simple, does not need sophisticated instruments, and is suitable for quality control application, bioavailability, and bioequivalency studies. Besides, its detection limits are comparable to other sophisticated chromatographic methods.

1. Introduction

Encouraged by the successful application of the NMNCl methodology to the determination of a similar α-methylene carbonyl functional group containing drugs, namely, warfarin [1], pentoxifylline, propafenone hydrochloride and acebutolol hydrochloride [2], the almost isosteric α-methylene sulfoxide group, such as proton pump inhibitors (PPIs) and the cyclic α-methylene carbonyl group, such as ketamine hydrochloride, griseofulvin, and levonorgestrel (unpublished results), we decided to investigate the possibility of extending the application of such methodology to drugs containing the isosteric α-methylene sulfone/sulfonamide functional groups, namely, methyl sulfonyl methane (MSM) (1), tinidazole (2), rofecoxib (3), and nimesulide (4).

Methyl sulfonyl methane (MSM) (1) is a relatively new dietary supplement form of sulfur that is found in our living tissues. MSM supports healthy connective tissues like tendons, ligaments, and muscle. Thus, it is important in conditions such as arthritis, muscle pains, and bursitis. MSM should be considered an integral part of any health care practice because of its physiological action, indirect importance, and current/future uses [3–5].

In this report, MSM was used as a model compound and was found to react successfully with NMNCl quantitatively yielding a fluorophore. Because there are marketed dosage forms containing MSM, it was decided to apply the developed method for its analysis in its marketed dietary supplement dosage forms in view of the rather elaborate and costly methodologies reported for its analysis in the available literature. The reported methods include Fourier-transform infrared (FT-IR) spectrometry [6], Raman spectroscopy [7], CIMS [8], GC [9], GC with flame ionization detector [10], GC with flame photometric detection [11], capillary
This paper describes the application and validation of the reaction of NMNCl with some drugs containing $\alpha$-methylene sulfone groups.

2. Results and Discussion

When 1, 2, 3, and 4 (for chemical structures and plausible pathway of the reaction, cf. Figure 1) were allowed to react with NMNCl under the optimal conditions specified for each, strong fluorescent products were obtained. The optimal wavelengths of excitation and emission of the reaction product were determined using synchronous wavelength search and listed in Table 1.

Different variables affecting the reaction between the chosen drugs and NMNCl, including sodium hydroxide concentration and volume, volume and concentration of the added NMNCl, and pH values, were studied to optimize the reaction conditions to give maximum fluorescence intensity (Figures 2, 3, and 4).

Under the optimum conditions for the reaction of NMNCl with the chosen drug, linear relationships between the fluorescence intensity and the drug concentrations were obtained in the following ranges: 1–150 μg/mL, 10–1000 ng/mL, 1–1800 ng/mL, and 30–2100 ng/mL for standard solutions of 1, 2, 3, and 4, respectively, and over concentration ranges of 5–150 μg/mL, 10–1000 ng/mL, 10–1700 ng/mL, and 30–2350 ng/mL for spiked human plasma samples of 1, 2, 3, and 4, respectively.

These results have revealed a good and dynamic linearity ranges of the proposed method with different drugs. The good linearity of these relations was indicated by the corresponding regression equations shown in Tables 2 and 3 for standard solutions and spiked human plasma samples, respectively.

2.1. Detection Limit (DL). Detection limits were practically determined according to the ICH topic Q2B (R1) [51] and found to be 0.5 μg/mL, 3 ng/mL, 0.33 ng/mL, and 10 ng/mL, for standard solutions and 0.7 μg/mL, 5 ng/mL, 0.6 ng/mL, and 18 ng/mL, for plasma samples of 1, 2, 3, and 4, respectively.

2.2. Quantitation Limit (QL). Quantitation limits were practically determined according to the ICH topic Q2B (R1) [51] and found to be 1 μg/mL, 10 ng/mL, 1 ng/mL, and 10 ng/mL, for standard solutions and 5 μg/mL, 10 ng/mL, 10 ng/mL, and 30 ng/mL, for plasma samples of 1, 2, 3, and 4, respectively.

2.3. Accuracy. The accuracy of the proposed method was studied according to the ICH topic Q2B (R1) [51], by preparing spiked human plasma samples containing various concentrations, lying within the linearity range of each drug, and analyzing them using the proposed method. The results, expressed as % recovery ± S.D., are shown in Table 4 for spiked human plasma samples.

2.4. Precision. The precision of the method was judged by performing intraday and interday triplicate analyses of different concentrations covering the linearity range of each drug.
Figure 1: Chemical structures of the analytes and plausible pathway for the reaction of NMNCl with α-methylene sulfone/sulfonamide functional groups of 1–4.

Figure 2: Effect of NaOH concentration and volume on fluorescence intensity of the reaction product of 1–4 with NMNCl. The variation of NaOH concentration is made at constant volume and that of NaOH volume at constant concentration.

drug in spiked human plasma samples. The results are reported as S.D. and coefficient of variation (C.V.) in Table 5 for spiked human plasma samples.

2.5. Specificity. To study the specificity of the proposed method, three synthetic mixtures of 1, 2, and 3 and two synthetic mixtures of 4 were prepared to contain the possible interfering substances used during pharmaceutical formulations. These mixtures were analyzed using the proposed method and the results, were expressed as % recovery ± S.D., and were as follows: 99.8% ± 3.0 for 1, 100.3% ± 2.8 for 2, 99.6% ± 3.5 for 3, and 100.7% ± 1.7 for 4.
Table 1: Optimum conditions for the fluorometric procedure.

| Drug | pH* | NaOH conc. (M) | NaOH volume (mL) | NMNCl conc. (mM) | NMNCl volume (mL) | Cooling time (min) | Heating time (min) | λ_ex (nm) | λ_em (nm) |
|------|-----|----------------|------------------|------------------|------------------|-------------------|-------------------|-----------|-----------|
| 1    | 3.0 | 6.0            | 1.1              | 1.0              | 0.9              | 9                 | 6                 | 350       | 395       |
| 2    | 3.2 | 5.0            | 1.0              | 2 × 10⁻¹         | 1.0              | 10                | 3                 | 336       | 391       |
| 3    | 2.5 | 7.0            | 0.9              | 4 × 10⁻¹         | 1.2              | 8                 | 5                 | 354       | 440       |
| 4    | 1.5 | 8.0            | 1.0              | 5 × 10⁻¹         | 0.9              | 7                 | 3                 | 325       | 375       |

* The reaction pH.

2.6. Assay of Pharmaceutical Preparations. All the pharmaceutical preparations available in the local market for each drug were analyzed using the proposed method. The results, expressed as % recovery ± S.D., are illustrated in Table 6.

2.7. Determination of 2 and 4 in Volunteer’s Blood. The success in the application of the highly sensitive proposed procedure for the determination of 2 and 4, in spiked human plasma samples with good accuracy and precision, encouraged the investigator to study its application for monitoring the drug level in the blood of a volunteer receiving 2 or 4 therapy. The level of 2 and 4 was monitored in the blood of volunteers, and their concentrations were found to be 48 μg/mL and 35 μg/mL, respectively, that lie in the therapeutic levels of 2 (47.7 ± 7.5 μg/mL) and 4 (38 ± 10.6 μg/mL).

3. Conclusion

The proposed method makes use of the high sensitivity and specificity of the fluorometric analysis to reach low limits of detection and quantitation for all the studied drugs in standard solutions, synthetic mixtures, pharmaceutical preparations, spiked human plasma samples, and patient’s or volunteer’s blood. The method is simple; it gives results comparable to those obtained by other techniques that require elaborate instrumentation and time-consuming sample preparation procedure.

The method showed good accuracy and precision suitable for quality assurance and could be recommended for
Table 2: Regression analysis parameters for the determination of 1–4 in standard solutions using the proposed method.

| Drug | Linearity range   | Slope  | Intercept  | $R^2$  |
|------|-------------------|--------|------------|-------|
|      |                   | Mean   | SE         | Mean  | SE    |       |
| 1    | 1–150 $\mu$g/mL  | 4.9890 | 0.011      | 105.66| 2.15  | 0.9997|
| 2    | 10–1000 ng/mL     | 0.8579 | 0.010      | 131.84| 1.60  | 0.9998|
| 3    | 1–1800 ng/mL      | 0.5130 | 0.003      | 72.63 | 1.10  | 0.9995|
| 4    | 30–2100 ng/mL     | 0.4155 | 0.005      | 113.20| 2.78  | 0.9999|

Average of triplicate analyses, 13 data points.

Table 3: Regression analysis parameters for the determination of 1–4 in spiked human plasma samples using the proposed method.

| Drug | Linearity range   | Slope  | Intercept  | $R^2$  |
|------|-------------------|--------|------------|-------|
|      |                   | Mean   | SE         | Mean  | SE    |       |
| 1    | 5–150 $\mu$g/mL  | 4.8849 | 0.100      | 118.53| 1.55  | 0.9991|
| 2    | 10–1000 ng/mL     | 0.7930 | 0.020      | 192.15| 1.70  | 0.999 |
| 3    | 10–1700 ng/mL     | 0.5342 | 0.010      | 49.64 | 1.57  | 0.9989|
| 4    | 30–2350 ng/mL     | 0.3110 | 0.003      | 254.48| 1.35  | 0.9995|

Average of triplicate analyses, 13 data points.

Table 4: Recovery data of 1–4 in spiked human plasma samples using the proposed method.

| Drug | Claimed drug concentration | *Recovered concentration | % Recovery | Mean % recovery ± S.D. | C.V. |
|------|----------------------------|--------------------------|------------|------------------------|------|
| 1    | 5 (μg/mL)                  | 5.02                     | 100.4%     |                        |      |
|      | 20                         | 20.20                    | 101.0%     |                        |      |
|      | 60                         | 59.00                    | 98.3%      |                        |      |
|      | 80                         | 78.00                    | 97.5%      |                        |      |
|      | 100                        | 102.30                   | 102.3%     |                        |      |
|      | 150                        | 153.00                   | 102.0%     |                        |      |
|      | 10                         | 9.8                      | 98.00%     |                        |      |
|      | 30                         | 30.5                     | 101.60%    |                        |      |
|      | 50                         | 51.0                     | 102.00%    |                        |      |
| 2    | 100                        | 102.0                    | 102.00%    |                        |      |
|      | 300                        | 295.0                    | 98.30%     |                        |      |
|      | 500                        | 490.0                    | 98.00%     |                        |      |
|      | 800                        | 810.0                    | 101.20%    |                        |      |
|      | 1000                       | 987.0                    | 98.70%     |                        |      |
| 3    | 10                         | 10.2                     | 102.0%     |                        |      |
|      | 100                        | 102.0                    | 102.0%     |                        |      |
|      | 300                        | 297.0                    | 99.0%      |                        |      |
|      | 800                        | 807.0                    | 100.9%     |                        |      |
|      | 1000                       | 991.0                    | 99.1%      |                        |      |
| 4    | 10                         | 10.2                     | 102.0%     |                        |      |
|      | 100                        | 102.0                    | 102.0%     |                        |      |
|      | 300                        | 297.0                    | 99.0%      |                        |      |
|      | 800                        | 807.0                    | 100.9%     |                        |      |
|      | 1000                       | 991.0                    | 99.1%      |                        |      |

Average of triplicate analyses.

Table 4: Recovery data of 1–4 in spiked human plasma samples using the proposed method.

| Drug | Claimed drug concentration | *Recovered concentration | % Recovery | Mean % recovery ± S.D. | C.V. |
|------|----------------------------|--------------------------|------------|------------------------|------|
| 1    | 5 (μg/mL)                  | 5.02                     | 100.4%     |                        |      |
|      | 20                         | 20.20                    | 101.0%     |                        |      |
|      | 60                         | 59.00                    | 98.3%      |                        |      |
|      | 80                         | 78.00                    | 97.5%      |                        |      |
|      | 100                        | 102.30                   | 102.3%     |                        |      |
|      | 150                        | 153.00                   | 102.0%     |                        |      |
|      | 10                         | 9.8                      | 98.00%     |                        |      |
|      | 30                         | 30.5                     | 101.60%    |                        |      |
|      | 50                         | 51.0                     | 102.00%    |                        |      |
| 2    | 100                        | 102.0                    | 102.00%    |                        |      |
|      | 300                        | 295.0                    | 98.30%     |                        |      |
|      | 500                        | 490.0                    | 98.00%     |                        |      |
|      | 800                        | 810.0                    | 101.20%    |                        |      |
|      | 1000                       | 987.0                    | 98.70%     |                        |      |
| 3    | 10                         | 10.2                     | 102.0%     |                        |      |
|      | 100                        | 102.0                    | 102.0%     |                        |      |
|      | 300                        | 297.0                    | 99.0%      |                        |      |
|      | 800                        | 807.0                    | 100.9%     |                        |      |
|      | 1000                       | 991.0                    | 99.1%      |                        |      |
| 4    | 30                         | 29.6                     | 98.7%      |                        |      |
|      | 100                        | 98.0                     | 98.0%      |                        |      |
|      | 500                        | 509.0                    | 101.8%     |                        |      |
|      | 1000                       | 1015.0                   | 101.0%     |                        |      |
| 5    | 1200                       | 1181.0                   | 98.4%      |                        |      |
|      | 1500                       | 152.5                    | 101.6%     |                        |      |
|      | 1800                       | 1809.0                   | 100.5%     |                        |      |
|      | 2100                       | 2345.0                   | 99.7%      |                        |      |

Average of triplicate analyses.
Table 5: Intraday and interday precision of 1–4 determination in plasma samples using the proposed method.

| Drug | Claimed conc. | Intraday | Interday |
|------|---------------|----------|----------|
|      | Found conc*   | S.D.     | C.V.     | Found conc* | S.D. | C.V. |
| 1 (μg/mL) | | | | | | |
| 5 | 5.03 | 0.02 | 0.4% | 4.9 | 0.71 | 0.14% |
| 20 | 20.1 | 0.07 | 0.4% | 19.7 | 0.21 | 1.10% |
| 60 | 61.3 | 0.90 | 1.5% | 58.6 | 0.99 | 1.70% |
| 80 | 78.0 | 0.14 | 1.7% | 83.0 | 2.12 | 2.60% |
| 100 | 104.0 | 2.80 | 2.8% | 97.0 | 2.12 | 2.15% |
| 150 | 154.0 | 2.80 | 1.9% | 146.0 | 2.80 | 1.90% |
| 2 (ng/mL) | | | | | | |
| 10 | 9.7 | 0.21 | 2.2% | 9.8 | 0.14 | 1.42% |
| 30 | 29.3 | 0.50 | 1.7% | 30.5 | 0.35 | 1.16% |
| 50 | 51.5 | 1.10 | 2.1% | 50.0 | 0.71 | 1.43% |
| 100 | 102.0 | 1.40 | 1.4% | 102.0 | 1.40 | 1.30% |
| 300 | 296.0 | 2.80 | 1.0% | 289.0 | 7.28 | 2.60% |
| 500 | 512.0 | 8.40 | 1.7% | 510.0 | 7.10 | 1.40% |
| 800 | 795.0 | 3.50 | 0.4% | 810.0 | 7.10 | 1.87% |
| 1000 | 985.0 | 10.60 | 1.1% | 985.0 | 10.60 | 1.10% |
| 3 (ng/mL) | | | | | | |
| 10 | 10.4 | 0.30 | 2.8% | 10.3 | 0.21 | 2.08% |
| 100 | 96.0 | 2.80 | 2.9% | 96.0 | 2.82 | 2.90% |
| 300 | 304.0 | 2.80 | 0.9% | 305.0 | 3.50 | 1.20% |
| 500 | 495.0 | 0.35 | 0.7% | 506.0 | 4.24 | 0.84% |
| 1000 | 1020.0 | 14.10 | 1.4% | 1020.0 | 14.10 | 1.40% |
| 1100 | 1125.0 | 17.70 | 1.6% | 1125.0 | 17.70 | 1.60% |
| 1500 | 1475.0 | 17.70 | 1.2% | 1485.0 | 10.60 | 0.71% |
| 1700 | 1720.0 | 14.10 | 0.8% | 1720.0 | 14.10 | 0.83% |
| 4 (ng/mL) | | | | | | |
| 30 | 29.4 | 0.40 | 1.4% | 30.3 | 0.21 | 0.70% |
| 100 | 98.0 | 1.40 | 1.4% | 104.0 | 2.83 | 2.80% |
| 500 | 505.0 | 3.50 | 0.70% | 491.0 | 6.36 | 1.28% |
| 1000 | 1015.0 | 10.60 | 1.1% | 980.0 | 14.10 | 1.40% |
| 1200 | 1185.0 | 10.60 | 0.90% | 1225.0 | 17.70 | 1.45% |
| 1500 | 1524.0 | 16.90 | 1.10% | 1529.0 | 20.50 | 1.35% |
| 1800 | 1815.0 | 10.60 | 0.60% | 1780.0 | 14.10 | 0.79% |
| 2350 | 2340.0 | 7.10 | 0.30% | 2360.0 | 7.10 | 0.30% |

* Average of triplicate analyses.

bioequivalency and bioavailability studies as well as for validation of cleaning methodology prior to line clearance during manufacture of said dosage forms.

The proposed method application could be extended to cover all available pharmaceutical preparations for each of the chosen drugs.

4. Experimental

4.1. Apparatus. Shimadzu RF 5301 PC spectrofluorometer.

4.2. Materials

4.2.1. Authentic Drugs. 1, 2, 3, and 4 working standards were supplied by Eva Pharma for Pharmaceutical Industries and Medical Appliances, Egypt, Medical Union Pharmaceuticals (MUP), Egypt, October Pharma, Egypt, and Sigma Pharmaceutical Industries, Egypt, respectively.

Plasma samples were purchased from the Central Blood Bank of Tanta University Hospital.

4.2.2. Other Chemicals. N1-Methyl nicotinamide chloride was obtained from Sigma Chemicals Co. Formic acid, sodium hydroxide, methanol, and all other chemicals were of analytical grade. Water used was doubly distilled.

4.2.3. Dosage Forms. MSM (1): MSM 1 g tablets (Eva Pharma).

Tinidazole (2): Fasigyn 500 mg tablets (Pfizer) and Protozol 500 mg tablets (MUP).

Rofecoxib (3): Romacox 25 mg tablets (October Pharma).
4.3. Reagents and Standard Solutions

4.3.1. Stock Standard Solutions of Drugs. Stock standard solutions were prepared in distilled water for 1, methanol for 2 and 4, and ethanol for 2 and 4 to contain 10 mg/mL, 10 mg/mL, 0.2 mg/mL, and 0.25 mg/mL for 1, 2, 3, and 4, respectively.

4.3.2. Serial Standard Solutions of Drugs. Aliquots of the stock solution were diluted quantitatively with the same solvent to obtain serial standard solutions in concentration ranging from 0.1 to 15 mg/mL, 0.1 to 10 μg/mL, 0.01 to 20 μg/mL and 0.1 to 250 μg/mL for 1, 2, 3, and 4, respectively.

4.4. Assay Solutions of Drugs in Synthetic Mixtures. Three synthetic mixtures containing 1 along various excipients, additives, and other nonactive ingredients commonly used in pharmaceutical formulations were prepared. The first mixture contained 1000 mg 1, 135 mg starch, 60 mg gelatin, and 8.0 mg magnesium stearate. The second mixture contained 1000 mg 1, 75 mg lactose, 30 mg starch, 60 mg gelatin, 8.0 mg magnesium stearate, and 42 mg tcalc. The third mixture contained 100 mg avicel instead of lactose and gelatin.

Three synthetic mixtures containing 2 were prepared. The first mixture contained 500 mg 2, 200 mg cellulose, 72 mg starch, 8.0 mg magnesium stearate, 8.0 mg polyethylene glycol and 1.0 mg titanium dioxide. The second mixture contained 500 mg 2 and, 100 mg lactose, 60 mg starch, 60 mg gelatin, 8.0 mg magnesium stearate and 72 mg tcalc. The third mixture contained 160 mg avicel instead of lactose and gelatin.

Three synthetic mixtures containing 3 were prepared. The first mixture contained 25 mg 3, 100 mg croscarmellose, 83.5 mg lactose, and 8.0 mg stearate. The second mixture contained 25 mg 3, 60 mg citric acid, 80 mg sodium citrate, and 10% sorbitol solution. The third mixture contained 25 mg 3, 235 mg lactose, 60 mg gelatin, 8.0 mg magnesium stearate, and 72 mg tcalc.

Two synthetic mixtures containing 4 along with various excipients and additives were prepared. The first mixture contained 100 mg 4, 200 mg lactose, 60 mg starch, 60 mg gelatin, 8.0 mg magnesium stearate, and 72 mg talc. The second mixture contained 260 mg avicel instead of lactose and gelatin.

Each synthetic mixture containing 1, 2, 3, or 4 was extracted with 100 mL of distilled water for 1, methanol for 2, or ethanol for 3 and 4, filtered, and the first 10 mL of the filtrate was rejected. Aliquots of the filtrate were diluted with the same solvents to obtain serial dilutions in concentrations ranging from 0.1 to 25 mg/mL, 0.1 to 10 μg/mL, 0.01 to 20 μg/mL and 0.1 to 25 μg/mL, for 1, 2, 3, and 4, respectively.

4.5. Assay Solutions of Drugs in Their Pharmaceutical Preparations. Twenty tablets were finely powdered, a quantity of the powder, equivalent to one tablet of 1–4, was transferred with the aid of several portions of distilled water for 1, methanol for 3 or ethanol for 2, 4 to a 100 mL volumetric flask and the volume was completed with the same solvent. The resulting solution was filtered and the first 10 mL of the filtrate was rejected. Aliquots of the filtrate were diluted with the same solvents to obtain 100 μg/mL, 6 μg/mL, 5 μg/mL and 6 μg/mL solutions, for 1, 2, 3 and 4, respectively.

4.6. Assay Solutions of Drugs in Spiked Human Plasma Samples

4.6.1. Serial Standard Solutions of the Drugs. Serial standard solutions were prepared in distilled water (for 1), in methanol (for 2), and in ethanol (for 3 and 4) in concentrations ranging from 1 to 150 mg/mL, 0.01 to 1 mg/mL, 0.001 to 2.0 mg/mL and 0.01 to 2.5 mg/mL of 1, 2, 3, and 4, respectively.

4.6.2. Preparation of Spiked Human Plasma Samples. Two hundred μL of each of the serial standard solutions of 1 were diluted with 1800 μL human plasma and vortex mixed to obtain concentrations ranging from 0.1 to 15 mg/mL, 2, 3, and 4 200 μL of each drug serial standard solution were evaporated; the residue was dissolved in 1800 μL human plasma and vortex mixed, 200 μL distilled water was added and vortex mixed to obtain 0.001–0.1 mg/mL, 0.0001–0.2 mg/mL, and 0.001–0.25 mg/mL of 2, 3, and 4, respectively.
4.7. Preparation of Assay Solutions of Drugs in Plasma Samples. Two hundred μL of spiked human plasma samples (cf. preparation of spiked human plasma samples) were mixed with 1800 μL methanol and centrifuged for 15 minutes to separate the precipitated protein. The clear supernatant was filtered through Millipore filter (0.45 μm) to obtain solutions in concentration range of 0.01–1.5 mg/mL, 0.1–10 μg/mL, 0.01–20 μg/mL, and 0.1–25 μg/mL for 1, 2, 3, and 4, respectively.

4.8. Determination of 2 and 4 in Volunteer’s Blood. Blood sample was withdrawn in a test tube to which heparin was previously added and dried. The sample was centrifuged to separate plasma and then treated as previously mentioned under preparation of assay solutions of 2 and 4 in plasma samples (cf. preparation of assay solutions of drugs in plasma samples).

4.9. N1-Methylnicotinamide Chloride Reagent (NMNCl). Ten mM solution NMNCl reagent was prepared by dissolving 17.262 g NMNCl in one liter of 10−2 N HCl. Aliquots of this solution were diluted with distilled water to obtain 1.0 mM, 2.0 × 10−1 mM, 4.0 × 10−1 mM, and 5.0 × 10−1 mM solutions.

4.10. General Fluorometric Procedure. One milliliter of each drug standard solutions, assay solutions of synthetic mixtures, assay solutions of pharmaceutical preparations, assay solutions of plasma samples, or the assay solution of the volunteer’s plasma was transferred to 10.0 mL screw-capped test tube. Solutions of sodium hydroxide and NMNCl were added. The mixture was cooled (in ice) for the indicated time, then the pH was adjusted using formic acid and heated for the indicated time and then was cooled in ice for 5 minutes (optimum NaOH concentration and volume, volume and concentration of added NMNCl, reaction pH values) and cooling and heating times are indicated in Table 1. The mixture was transferred to 10.0 mL volumetric flask, and the resulting solution was completed using distilled water. In case of 4, the pH of the reaction product was adjusted to 10.0 before completing to volume with distilled water. The intensity of the resulting fluorescence was measured at the optimal wavelengths indicated in Table 1. The fluorometric measurements were performed against reagent blank experiments. Concentrations of the drugs were calculated from the corresponding calibration graphs prepared simultaneously.

References

[1] M. A. Eldawy, M. M. Mabrouk, and R. A. Elbarbary, “Spectrofluorimetric determination of warfarin sodium by using N1-methylnicotinamide chloride as a fluorogenic agent,” Journal of Association of Official Analytical Chemists International, vol. 88, pp. 455–461, 2005.
[2] M. A. El Dawy, M. M. Mabrouk, and R. A. El Barbary, “Spectrofluorimetric determination of drugs containing active methylene group using N-methyl nicotinamide chloride as a fluorogenic agent,” Chemical and Pharmaceutical Bulletin, vol. 54, no. 7, pp. 1026–1029, 2006.
[3] D. Mitchell, S. J. Bock, and M. S. M. Sulfur, “Natural Health and Longevity Resource Center,” October 2010, http://www.all-natural.com/msm.html.
[4] MSM, “Life Extension Foundation,” October 2010, http://www.legs.org/newshop/items/item00451.html.
[5] MSM, “Natural Ways to Health,” October 2010, http://www.naturalways.com/MSM.htm.
[6] C. Arsenne, I. Barnes, K. H. Becker, and R. Mocanu, “FT-IR product study on the photo-oxidation of dimethyl sulphide in the presence of NO—temperature dependence,” Atmospheric Environment, vol. 35, no. 22, pp. 3769–3780, 2001.
[7] Y. C. Ling, T. J. Vickers, and C. K. Mann, “Background correction in raman spectroscopic determination of dimethyl-sulfone, sulfate, and bisulfite,” Applied Spectroscopy, vol. 39, pp. 463–470, 1983.
[8] H. Berresheim, D. J. Tanner, and F. L. Eisele, “Method for real-time detection of dimethyl sulfone in ambient air,” Analytical Chemistry, vol. 65, no. 21, pp. 3168–3170, 1993.
[9] R. F. Lang and C. J. Brown, “Determination of dimethyl sulfoxide and dimethyl sulfone in air,” Analytical Chemistry, vol. 63, no. 2, pp. 185–189, 1991.
[10] A. C. Mehta, S. Peeker, C. Acomb, and R. T. Calvert, “Rapid gas chromatographic determination of dimethyl sulphoxide and its metabolite dimethyl sulphone in plasma and urine,” Journal of Chromatography—Biomedical Applications, vol. 383, no. 2, pp. 400–404, 1986.
[11] N. Moreira, P. Guedes De Pinho, and I. Vasconcelos, “Method for analysis of heavy sulphur compounds using gas chromatography with flame photometric detection,” Analytica Chimica Acta, vol. 513, no. 1, pp. 183–189, 2004.
[12] J. L. Liu, S. Li, Z. H. Li, and H. Ma, “Capillary gas chromatographic separation and determination of dimethyl sulfoxide and dimethyl sulfone,” Lihua Jianyan Huaxue Fence, vol. 38, pp. 283–284, 2002.
[13] A. Willsie, A. M. Belcher, G. Preti et al., “Identification of major histocompatibility complex-regulated body odors by statistical analysis of a comparative gas chromatography/mass spectrometry experiment,” Analytical Chemistry, vol. 77, no. 8, pp. 2348–2361, 2005.
[14] A. C. Silva Ferreira, P. Rodrigues, T. Hogg, and P. G. De Pinho, “Influence of some technological parameters on the formation of dimethyl sulfide, 2-mercaptoethanol, methionol, and dimethyl sulfone in port wines,” Journal of Agricultural and Food Chemistry, vol. 51, no. 3, pp. 727–732, 2003.
[15] D. T. T. Vu, “SPME/GC-MS characterization of volatiles associated with methamphetamine: toward the development of a pseudomethamphetamine training material,” Journal of Forensic Sciences, vol. 46, no. 5, pp. 1014–1024, 2001.
[16] C. Pérez, C. Denoyer, P. Tournayre, and J. L. Berdagué, “Fast characterization of cheeses by dynamic headspace-mass spectrometry,” Analytical Chemistry, vol. 74, no. 6, pp. 1386–1392, 2002.
[17] D. Saccù, P. Bogoni, and G. Procida, “Aloe exudate: characterization with simultaneous distillation-extraction and dynamic headspace,” Journal of Chromatographic Science, vol. 39, no. 6, pp. 222–228, 2001.
[18] British Pharmacopoeia, Her-Majesty’s Stationary Office, London, UK, 2005.
[20] United States Pharmacopeia, vol. 28, United States Pharmacopeia Convention, Washington, DC, USA, 2005.
[21] J. Z. Wang, B. Liu, and X. Q. Sun, “Determination of tinidazole by fluorimetry,” Fenxi Ceshi Xuebao, vol. 23, pp. 76–79, 2004.
[22] X. C. Fu, G. P. Wang, Y. H. Wang, and W. Q. Liang, “A predictive model for the release of slightly water-soluble drugs from HPMC matrices,” Pharmazie, vol. 59, no. 8, pp. 624–626, 2004.
[23] C. H. Yang, “Voltammetric determination of tinidazole using a glassy carbon electrode modified with single-wall carbon nanotubes,” Analytical Sciences, vol. 20, no. 5, pp. 821–824, 2004.
[24] A. P. Argekar and J. G. Sawant, “Simultaneous determination of ciprofloxacin hydrochloride and tinidazole in tablets by HPTLC,” Journal of Planar Chromatography—Modern TLC, vol. 12, no. 3, pp. 202–206, 1999.
[25] A. P. Argekar and S. G. Powar, “Simultaneous determination of diloxanide furoate and tinidazole in tablets by high-performance thin-layer chromatography,” Journal of Planar Chromatography—Modern TLC, vol. 12, no. 6, pp. 452–455, 1999.
[26] H. Sun, F. Wang, L. Ai, C. Guo, and R. Chen, “Validated method for determination of eight banned nitroimidazole residues in natural casings by LC/MS/MS with Solid-Phase Extraction,” Journal of Association of Official Analytical Chemists International, vol. 92, no. 2, pp. 612–621, 2009.
[27] Y. J. Yang, X. Y. Li, and H. Y. Li, “HPLC determination of related substances and content of tinidazole colon targeting tablets,” Yaoxu Fenxi Zazhi, vol. 24, pp. 614–616, 2004.
[28] G. S. Sadana and M. V. Gaonkar, Indian Drugs, vol. 22, pp. 241–246, 1989.
[29] Y. Cheng, E. Ho, B. Subramanyam, and J. L. Tseng, “Measurements of drug-protein binding by using immobilized human serum albumin liquid chromatography-mass spectrometry,” Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, vol. 809, no. 1, pp. 67–73, 2004.
[30] Vioxx® (rofecoxib) Information Center. Merck & Co., Inc., October 2010 http://www.merck.com/newsroom/vioxx_withdrawal.
[31] Vioxx information, “Defective drugs, elsticine,” October 2009,http://www.adrugrecall.com/vioxx/information.html.
[32] M. A. Shehata, A. Ashour, N. Y. Hassan, A. S. Fayed, and B. A. El-Zeany, “Liquid chromatograph and chemometric methods for determination of rofecoxib in presence of its photodegrade and alkaline degradation products,” Analytica Chimica Acta, vol. 519, no. 1, pp. 23–30, 2004.
[33] N. Erd and T. G. Altuntas, “Comparison of derivative spectrophotometric and liquid chromatographic methods for the determination of rofecoxib,” Pharmazie, vol. 59, no. 6, pp. 453–456, 2004.
[34] A. Duran, B. Bekçe, and H. N. Doğan, “Quantitative determination of rofecoxib in pharmaceutical preparations,” Pharmazie, vol. 59, no. 1, pp. 71–72, 2004.
[35] N. Kaul, S. R. Dhaneshwar, H. Agrawal, A. Kakad, and B. Patil, “Application of HPLC and HPTLC for the simultaneous determination of tizanidine and rofecoxib in pharmaceutical dosage form,” Journal of Pharmaceutical and Biomedical Analysis, vol. 37, no. 1, pp. 27–38, 2005.
[36] M. Amini, M. P. Hamedani, M. Vosooghi, M. Nabavi, and A. Shafiee, “Pre-column derivatization of rofecoxib for determination in serum by HPLC,” Analytical and Bioanalytical Chemistry, vol. 382, no. 5, pp. 1265–1268, 2005.
[37] P. R. Tiller, L. A. Romanynhyn, and U. D. Newe, “Fast LC/MS in the analysis of small molecules,” Analytical and Bioanalytical Chemistry, vol. 377, no. 5, pp. 788–802, 2003.
[38] Nimesulide, “Pharmaceutical Industry, India,” October 2010, http://www.pharma-india.com/nimesulide.html.
[39] British Pharmacopoeia, Her-Majesty’s Stationary Office, London, UK, 2005.
[40] Nimesulide Information, “Helsinn Healthcare SA,” October 2010, http://www.nimesulide.net/nimesulide.htm.
[41] M. Blanco, M. A. Romero, and M. Alcalà, “Strategies for constructing the calibration set for a near infrared spectroscopic quantitation method,” Talanta, vol. 64, no. 3, pp. 597–602, 2004.
[42] D. Mrinalini, A. Madgulkar, D. J. Vajale, A. Ayate, and A. Zambre, “Simultaneous spectrophotometric estimation of nimesulide and chloroxazone in tablet dosage form,” Indian Drugs, vol. 38, no. 11, pp. 576–579, 2001.
[43] H. Oliveira, M. Lúcio, B. De Castro, P. Gameiro, J. L. F. C. Lima, and S. Reis, “Partition and location of nimesulide in EPC liposomes: a spectrophotometric and fluorescence study,” Analytical and Bioanalytical Chemistry, vol. 377, no. 2, pp. 293–298, 2003.
[44] S. G. Navalgund, P. S. Prabhu, P. S. Sahasrabadhe, H. K. Deepa, and R. T. Sane, “A simple colorimetric method for the determination of nimesulide from its pharmaceutical preparation,” Indian Drugs, vol. 37, no. 4, pp. 209–210, 2000.
[45] R. I. L. Catarino, A. C. L. Conceição, M. B. Q. García, M. L. S. González, J. L. F. C. Lima, and M. M. C. Dos Santos, “Flow amperometric determination of pharmaceuticals with on-line electrode surface renewal,” Journal of Pharmaceutical and Biomedical Analysis, vol. 33, no. 4, pp. 571–580, 2003.
[46] S. Furlanetto, S. Orlandini, G. Aldini, R. Gotti, E. Dreassi, and S. Pinzaui, “Designing experiments to optimise and validate the adsorptive stripping voltammetric determination of nimesulide,” Analytica Chimica Acta, vol. 413, no. 1–2, pp. 229–239, 2000.
[47] C. M. B. Rolim, V. Porta, and S. Storpirits, “Quantitation of nimesulide in human plasma by high-performance liquid chromatography with ultraviolet absorbance detection and its application to a bioequivalence study,” Arzneimittel-Forschung, vol. 57, no. 6, pp. 537–541, 2007.
[48] A. Maltese, F. Maugeri, and C. Bucolo, “Rapid determination of nimesulide in rabbit aqueous humor by liquid chromatography,” Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, vol. 804, no. 2, pp. 441–443, 2004.
[49] R. E. Barrientos-Astigarraga, Y. B. Vannuchi, M. Sucupira, R. A. Moreno, M. N. Muscará, and G. De Nucci, “Quantification of nimesulide in human plasma by high-performance liquid chromatography/tandem mass spectrometry. Application to bioequivalence studies,” Journal of Mass Spectrometry, vol. 36, no. 12, pp. 1281–1286, 2001.
[50] H. Nakamura and Z. Tamura, “Fluorometric assay of α-methylene carbonyl compounds with N-methyl nicotinamide chloride,” Analytical Chemistry, vol. 50, no. 14, pp. 2047–2051, 1978.
[51] “Validation of Analytical Procedures: Text and Methodology ICH,” October 2010, http://www.ich.org/cache/compo/363-272-1.html#Q2A.
